1921
Volume 98, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Two rotavirus vaccines, RotaTeq and Rotarix, are licensed for global use; however, the protection they confer to unvaccinated individuals through indirect effects remains unknown. We systematically reviewed the literature and quantified indirect rotavirus vaccine effectiveness (VE) for preventing rotavirus hospitalization in children aged less than 5 years. From 148 identified abstracts, 14 studies met our eligibility criteria. In our main analysis using a random-effects model, indirect rotavirus VE was 48% (95% confidence interval [CI]: 39–55%). In a subgroup analysis by country income level, indirect VE was greater in high-income countries (52%; 95% CI: 43–60%) than in low- and middle-income countries (LMICs) (25%; 95% CI: 5–41%). In a sensitivity analysis using a quality-effects model, the indirect VE in LMICs was not statistically significant (25%; 95% CI: 0–44%). Our findings highlight the importance of increasing rotavirus vaccine coverage, particularly in LMICs where evidence for indirect VE is limited and rotavirus burden is high.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0705
2018-04-04
2018-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/4/tpmd170705.html?itemId=/content/journals/10.4269/ajtmh.17-0705&mimeType=html&fmt=ahah

References

  1. GBD 2015 DALYs and HALE Collaborators, 2016. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388: 16031658.
  2. GBD Diarrhoeal Diseases Collaborators, 2017. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 17: 909948.
  3. World Health Organization, 2013. Rotavirus vaccines. Wkly Epidemiol Rec 88: 4964.
  4. PATH, 2016. Country National Immunization Program (NIP) Introductions of Rotavirus Vaccine. Available at: http://www.path.org/vaccineresources/files/PATH-Country-Introduction-Table-EN-2016.05.01.pdf. Accessed June 29, 2017.
  5. Lamberti LM, Ashraf S, Walker CLF, Black RE, , 2016. A systematic review of the effect of rotavirus vaccination on diarrhea outcomes among children younger than 5 years. Pediatr Infect Dis J 35: 992998.
  6. Munos MK, Walker CLF, Black RE, , 2010. The effect of rotavirus vaccine on diarrhoea mortality. Int J Epidemiol 39 (Suppl 1): i56i62.
  7. Fischer Walker CL, Black RE, , 2011. Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size. BMC Public Health 11 (Suppl 3): S16.
  8. Panozzo CA, Becker-Dreps S, Pate V, Weber DJ, Funk MJ, Stuermer T, Brookhart MA, , 2014. Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007–2010. Am J Epidemiol 179: 895909.
  9. Pollard SL, Malpica-Llanos T, Friberg IK, Fischer-Walker C, Ashraf S, Walker N, , 2015. Estimating the herd immunity effect of rotavirus vaccine. Vaccine 33: 37953800.
  10. Seybolt LM, Bégué RE, , 2012. Rotavirus vaccination and herd immunity: an evidence-based review. Pediatr Health Med Ther 3: 2537.
  11. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, , 2009. Part 5: complex data structures. In: Introduction to Meta-Analysis. Available at: https://www.meta-analysis.com/downloads/Meta-analysis%20Studies%20with%20multiple%20subgroups%20or%20outcomes.pdf. Accessed July 18, 2017.
  12. Statacorp, 2013. Stata Statistical Software: Release 13. College Station, TX: Statacorp LP. Available at: https://www.stata.com/stata13/. Accessed August 1, 2017.
  13. Doi SAR, Thalib L, , 2008. A quality-effects model for meta-analysis. Epidemiology 19: 94100.
  14. Epi Gear, , 2016. MetaXL Version 5.3. Available at: http://www.epigear.com/index_files/metaxl.html. Accessed August 1, 2017.
  15. Dey A, Wang H, Menzies R, Macartney K, , 2012. Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Med J Aust 197: 453457.
  16. Yen C, 2011. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 30 (Suppl): S6S10.
  17. Field EJ, Vally H, Grimwood K, Lambert SB, , 2010. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 126: e506e512.
  18. Raes M, Strens D, Vergison A, Verghote M, Standaert B, , 2011. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 30: e120e125.
  19. Wilson SE, Rosella LC, Wang J, Le Saux N, Crowcroft NS, Harris T, Bolotin S, Deeks SL, , 2016. Population-level impact of Ontario’s infant rotavirus immunization program: evidence of direct and indirect effects. PLoS One 11: e0154340.
  20. Sáfadi MAP, Berezin EN, Munford V, Almeida FJ, de Moraes JC, Pinheiro CF, Racz ML, , 2010. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in São Paulo, Brazil. Pediatr Infect Dis J 29: 10191022.
  21. Bégué RE, Perrin K, , 2010. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics 126: e40e45.
  22. Atchison CJ, Stowe J, Andrews N, Collins S, Allen DJ, Nawaz S, Brown D, Ramsay ME, Ladhani SN, , 2016. Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England and Wales. J Infect Dis 213: 243249.
  23. Leshem E, Moritz RE, Curns AT, Zhou F, Tate JE, Lopman BA, Parashar UD, , 2014. Rotavirus vaccines and health care utilization for diarrhea in the United States (2007–2011). Pediatrics 134: 1523.
  24. Eberly MD, Gorman GH, Eide MB, Olsen CH, Rajnik M, , 2011. The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents. Vaccine 29: 650659.
  25. Cortes JE, Curns AT, Tate JE, Cortese MM, Patel MM, Zhou F, Parashar UD, , 2011. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med 365: 11081117.
  26. Gheorghita S, 2016. Impact of rotavirus vaccine introduction and vaccine effectiveness in the Republic of Moldova. Clin Infect Dis 62 (Suppl 2): S140S146.
  27. Zaman K, 2017. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial. PLoS Med 14: e1002282.
  28. Glass RI, Parashar U, Patel M, Gentsch J, Jiang B, , 2014. Rotavirus vaccines: successes and challenges. J Infect 68 (Suppl 1): S9S18.
  29. John TJ, Samuel R, , 2000. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 16: 601606.
  30. Fine P, Eames K, Heymann DL, , 2011. “Herd immunity”: a rough guide. Clin Infect Dis 52: 911916.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0705
Loading
/content/journals/10.4269/ajtmh.17-0705
Loading

Data & Media loading...

Supplementary Data

Supplemental Figure and Table

  • Received : 07 Sep 2017
  • Accepted : 31 Dec 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error